Ascentage Pharma Group International (AAPG) Other Non-Current Liabilities (2023 - 2025)

Ascentage Pharma Group International (AAPG) has reported Other Non-Current Liabilities for 3 consecutive years, with $1.7 million the latest figure, recorded in Q4 2025.

• Quarterly Other Non-Current Liabilities rose 94.21% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (up 94.21% YoY) and the FY2025 annual result came in at $1.7 million, up 100.0% from the prior year.
• Other Non-Current Liabilities climbed to $1.7 million in Q4 2025 per AAPG's latest filing, from $1.1 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for AAPG reached as high as $2.5 million in Q4 2023 and fell as low as $873439.4 in Q4 2024.
• A 3-year average of $1.5 million and a median of $1.4 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities slumped 65.63% — and 2025, when it jumped 94.21%.
• Year by year, Other Non-Current Liabilities stood at $2.5 million in 2023, then sank by 65.63% to $873439.4 in 2024, then soared by 94.21% to $1.7 million in 2025.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.7 million, $1.1 million, and $873439.4 for Q4 2025, Q2 2025, and Q4 2024 respectively.